{"id":12749,"date":"2023-04-24T07:34:38","date_gmt":"2023-04-24T07:34:38","guid":{"rendered":"http:\/\/novinor.com\/?p=12749"},"modified":"2023-07-05T17:54:44","modified_gmt":"2023-07-05T17:54:44","slug":"ngen-supports-commercial-manufacturing-of-cell-and-gene-therapies-in-canada-with-a-10-5-million-contribution","status":"publish","type":"post","link":"https:\/\/novinor.com\/en\/ngen-supports-commercial-manufacturing-of-cell-and-gene-therapies-in-canada-with-a-10-5-million-contribution\/","title":{"rendered":"NGen supports commercial manufacturing of cell and gene therapies in Canada with a $10.5 million contribution"},"content":{"rendered":"

Novinor wishes to replicate in Val-d’Or, for northern logistics and connectivity in remote areas, what NGen will do in Hamilton for TCG.<\/p>\n

In fact, we want to gather around the future Novinor center the most important players in the industries related to mining, forestry and others, so that Val-d’Or area becomes the hub for these sectors of activity.<\/em><\/strong><\/p>\n

The biomanufacturing of cellular and gene products allows the development of new advanced therapies (called TCG – “Cellular and Gene Therapies”). However, it requires a complex infrastructure and expertise that does not currently exist on a commercial scale in Canada.<\/p>\n

NGen<\/a>, the industry organization that leads Canada’s Global Innovation Cluster for Advanced Manufacturing, wants to change that. That’s why it has announced a $10.5 million contribution to a $34.8 million project led by OmniaBio and its partners ExCellThera<\/a> (Montreal), MorphoCell Technologies<\/a> (Montreal), Aspect Biosystems<\/a> (Vancouver) and CATTI<\/a> (Montreal).<\/h5>\n

This project is expected to result in the creation of a dedicated biofabrication center of excellence, the largest facility of its kind in the country. Located at McMaster Innovation Park in Hamilton, Ontario, the center will open in three phases between 2024 and 2026.<\/p>\n

The investment and development work in this critical manufacturing sub-sector will build technology absorption capacity for the growing number of advanced therapies currently in clinical and pre-clinical development in Canada that would otherwise have to be manufactured abroad.<\/p>\n

This project is one of NGen’s largest investments to date and is designed to secure Canada’s place as a world leader in life sciences by focusing on three core objectives<\/p>\n

    \n
  1. Build national expertise and world-class manufacturing capabilities;<\/strong><\/li>\n
  2. Build a pipeline of Canadian TCG companies;<\/strong><\/li>\n
  3. Develop Canada’s future workforce.<\/strong><\/li>\n<\/ol>\n

    \u00ab “Canada is on its way to becoming a world leader in the life sciences sector, and we are proud to support projects that contribute to this goal. This new $34 million project, led by OmniaBio and its consortium partners, will help strengthen Canada’s leadership and prepare more Canadians for good, high-paying jobs in this field. The project is expected to create hundreds of jobs in the short term and will have a positive impact on Canada and the international community. <\/em>\u00bb<\/p>\n